CervoMed to present new neflamapimod Phase 2 data in Lewy body dementia at AAIC 2026

CervoMed Inc.

CervoMed Inc.

CRVO

0.00
  • CervoMed flagged five AAIC 2026 presentations on neflamapimod in dementia with Lewy bodies, including Phase 2 exploratory efficacy and biomarker analyses.
  • Updates include MRI data on basal forebrain atrophy as a potential disease-progression biomarker from the RewinD-LB Phase 2 trial.
  • Company will also present first clinical results from a 24-week open-label Phase 2 study of neflamapimod 80 mg twice daily.
  • AAIC runs July 12-15 in London; no regulatory approvals or pivotal-trial starts were announced.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.